Vitamin K2 Market is expected to reach US$ 11,60,779.02 Thousands by 2030

Growing Cases of Osteoporosis in Adults and Newborns Drive Vitamin K2 Market Growth 

According to our new research study on "Vitamin K2 Market Forecast to 2030 – Global Analysis – by Product, Dosage Forms, Source, and Application," the market was valued at US$ 1,44,571.42 Thousands in 2022 and is projected to reach US$ 11,60,779.02 Thousands by 2030; it is estimated to grow at CAGR of 29.7% from 2022 to 2030.

Osteoporosis is an increasingly common health issue affecting adults and babies, a disorder marked by weakening and fragile bones. According to the International Osteoporosis Foundation 2022, osteoporosis causes more than 8.9 million fractures every year globally, resulting in osteoporotic fractures every 3 seconds. Medical professionals are concerned about the surge in osteoporosis-related bone distortion cases.

Vitamin K2 Market, by Product – 2022 and 2030

Vitamin K2 is a lesser-known vitamin K essential for maintaining healthy calcium metabolism and bone density. It stimulates proteins that transfer calcium from the bloodstream into the bones to ensure adequate mineralization and strength. The nutrient aids in avoiding osteoporosis-related bone fractures and deformities by improving calcium absorption. Adult osteoporosis cases frequently result from hormonal changes, age-related bone loss, or inadequate food intake. Vitamin K2 supplementation has demonstrated promising outcomes in enhancing bone mineral density and lowering fracture risk among adults. In addition, women are the main target for bone health products due to their higher incidence of osteoporosis. The increasing incidence of osteoporosis-related difficulties continues to be a key focus for functional foods and supplements such as calcium and vitamin D are the primary components supporting bone health. Calcium is the main mineral component of bones, while vitamin helps in calcium absorption. However, as consumers are becoming more aware of the benefits of vitamin K2, its availability in foods and supplements is rising. In addition, it has been proposed that vitamin K2 aids in reducing the activity of osteoclast cells, which are responsible for bone deterioration, further protecting bone integrity.  

Newborns can develop osteoporosis, especially preterm babies. They are more prone to fractures since their bones are immature and weak. Vitamin K2 improves bone growth and lessens the likelihood of bone abnormalities in the therapy regimens for these infants. Their skeletal development is accelerated by vitamin K2 supplementation, which supports the naturally occurring processes during the early stages of life. Thus, the growing number of adult and neonatal incidences of osteoporosis-related bone abnormalities creates an urgent need for efficient preventative measures and treatment approaches. Thus, vitamin K2 supplementation acts as a potential supplementary therapy that helps in calcium metabolism, bone mineralization, and the prevention of fractures. All these factors are driving the market growth.    

The Vitamin K2 market is segmented as follows:

The “vitamin K2 Market” is segmented on the basis of product, dosage forms, source, application, and geography. The vitamin K2 market, by product, is segmented into MK-4, MK-7, and combination drugs. In 2022, the MK-7 segment held the largest market share, and it is estimated to register the fastest CAGR during 2022–2030.  Menaquinone-7 (MK-7) is an advanced, fat-soluble form of vitamin K2 that serves multiple bodily functions. Only vitamin K2 in the form of MK-7 has been proven to provide 24-hour protection to bones and teeth from a single daily dose. MK-7 has a much longer half-life in the body and stays in the blood the longest than other forms of vitamin K2, owing to its presence not only in liver tissues but also in bones, arteries, and soft tissues. Therefore, MK-7 supplementation must only be taken once daily. According to MenaQ7, 45 mcg of MK-7 per day can increase carboxylation and activate vitamin K-dependent proteins, such as osteocalcin for bone health and Matrix GLA Protein (MGP) for heart health.  

Region Analysis – Vitamin K2 Market

In terms of geography, the global Vitamin K2 market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.

The market in North America is further divided into the US, Canada, and Mexico. North America holds the largest share of the vitamin K2 market. The market growth in North America is attributed to the rising adoption of nutraceutical supplements for vitamin K2. In addition, the increasing prevalence of cardiovascular diseases and orthopedic disorders, along with rising cases of vitamin K2 deficiency in children and geriatric population, is expected to fuel the vitamin K2 market.

The US accounts for the largest share of the vitamin K2 market in North America. The increasing prevalence of cardiovascular diseases and orthopedic disorders, such as osteoporosis and arthritis, has increased the demand for vitamin K2, as it helps in the better absorption of calcium and other nutrients, strengthening cardiac and bone health. According to the Centers for Disease Control and Prevention (CDC), in 2021, ~695,000 people died from heart disease in the US, coronary heart disease being the most common type of heart disease that resulted in the death of 375,476 people in the country. Moreover, various strategic developments such as product launches, acquisitions, and mergers have been taking place in the country, which are contributing to the market growth. In October 2022, Kappa Bioscience launched its first organic grade vitamin K2-MK7 in the US market under the brand name K2Vital. It is the first US Department of Agriculture (USDA) organic-certified all-trans, all-bioactive vitamin K2-MK7 for oil-based health applications in the US market. Therefore, the rising prevalence of cardiovascular diseases and orthopedic disorders, along with an increase in strategic collaboration, is expected to drive the vitamin K2 market growth in the US.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com